Imaging Standards for Clinical Trials: A Picture Worth 1,000 Guidance Documents
This article was originally published in RPM Report
Executive Summary
FDA is signaling its commitment to validating surrogate endpoints by agreeing to set standards on the use of imaging techniques in clinical trials. But industry will have to wait for a definitive answer: the document isn't slated for released until 2011.
You may also be interested in...
Pharma Catches a Break: Alzheimer's Drug Development Gets Rare Congressional Boost
Wyeth has been working hard to generate support for Alzheimer's drug development and easing FDA approval standards. One sign of success: a call to Capitol Hill for a friendly hearing.
Pharma Catches a Break: Alzheimer's Drug Development Gets Rare Congressional Boost
Wyeth has been working hard to generate support for Alzheimer's drug development and easing FDA approval standards. One sign of success: a call to Capitol Hill for a friendly hearing.
Torcetrapib's Silver Lining
What looks like bad news for the future of the CEPT inhibitor class of HDL-raising drugs may have a hidden silver lining for pharmaceutical companies interested in advancing the use of imaging as a clinical trial endpoint.